These innovative molecules represent a significant leap in the treatment of type 2 diabetes. Retatrutide, a combined GLP-1 and GIP receptor agonist, demonstrates exceptional efficacy in lowering blood glucose levels. https://abelebfn362001.isblog.net/novel-glp-1-receptor-agonists-retatrutide-and-trizepatide-56179638